The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Cannabidiol inhibits paclitaxel‐induced neuropathic pain through 5‐HT1A receptors without diminishing nervous system function or chemotherapy efficacy
Open accessAbstract
Background and Purpose: Paclitaxel (PAC) is associated with chemotherapy‐induced neuropathic pain (CIPN) that can lead to the cessation of treatment in cancer patients even in the absence of alternate therapies. We previously reported that chronic administration of the non‐psychoactive cannabinoid cannabidiol (CBD) prevents PAC‐induced mechanical and thermal sensitivity in mice. Hence, we sought to determine receptor mechanisms by which CBD inhibits CIPN and whether CBD negatively effects nervous system function or chemotherapy efficacy. Experimental Approach: The ability of acute CBD pretreatment to prevent PAC‐induced mechanical sensitivity was assessed, as was the effect of CBD on place conditioning and on an operant‐conditioned learning and memory task. The potential interaction of CBD and PAC on breast cancer cell viability was determined using the MTT assay. Key Results: PAC‐induced mechanical sensitivity was prevented by administration of CBD (2.5 – 10 mg·kg−1) in female C57Bl/6 mice. This effect was reversed by co‐administration of the 5‐HT 1A antagonist WAY 100635, but not the CB 1 antagonist SR141716 or the CB 2 antagonist SR144528. CBD produced no conditioned rewarding effects and did not affect conditioned learning and memory. Also, CBD + PAC combinations produce additive to synergistic inhibition of breast cancer cell viability. Conclusions and Implications: Our data suggest that CBD is protective against PAC‐induced neurotoxicity mediated in part by the 5‐HT 1A receptor system. Furthermore, CBD treatment was devoid of conditioned rewarding effects or cognitive impairment and did not attenuate PAC‐induced inhibition of breast cancer cell viability. Hence, adjunct treatment with CBD during PAC chemotherapy may be safe and effective in the prevention or attenuation of CIPN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
El‐Remessy, A. B., Tang, Y., Zhu, G., Matragoon, S., Khalifa, Y., Liu, E. K., Liu, J.-Y., Hanson, E. M., Mian, S. I., Fatteh, N., et al. (2008) · PubMed · Cited by 70
RetractedChou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Efficient Analysis of Experimental Observations
Dixon, W. J. (1980) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.20.040180.002301 · Cited by 2,208
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment
Baron, R., Binder, A., & Wasner, G. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70143-5 · Cited by 1,816
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
The evidence for pharmacological treatment of neuropathic pain
Finnerup, N. B., Sindrup, S. H., & Jensen, T. S. (2010) · Pain · doi:10.1016/j.pain.2010.06.019 · Cited by 1,045
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
Cited by
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
De Gregorio, D., McLaughlin, R. J., Posa, L., Ochoa-Sanchez, R., Enns, J., Lopez-Canul, M., Aboud, M., Maione, S., Comai, S., & Gobbi, G. (2019) · Pain · doi:10.1097/j.pain.0000000000001386 · Cited by 393
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 376
Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain
Sisignano, M., Baron, R., Scholich, K., & Geisslinger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.211 · Cited by 344
Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals
Williamson, E. M., Liu, X., & Izzo, A. A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14943 · Cited by 304
Li, Y., Song, W., Tong, Y., Zhang, X., Zhao, J., Gao, X., Yong, J., & Wang, H. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02040-8 · Cited by 295
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Mlost, J., Bryk, M., & Starowicz, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228870 · Cited by 285
Diversity of molecular targets and signaling pathways for CBD
de Almeida, D. L., & Devi, L. A. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.682 · Cited by 257
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Hutchison, K. E., Hagerty, S. L., Galinkin, J., Bryan, A. D., & Bidwell, L. C. (2019) · Cannabis & Cannabinoid Research · doi:10.1089/can.2018.0052 · Cited by 18
Metadata
- Authors
- Ward, S. J., McAllister, S. D., Kawamura, R., Murase, R., Neelakantan, H., & Walker, E. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-01-13
- Volume
- 171
- Issue
- 3
- Pages
- 636-645
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2105547810
- Cited by
- 276
- References
- 66
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.